Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
170.18
+0.22 (+0.13%)
Products, Earnings Announcements

Janssen Submits Application Seeking U.S. FDA Approval Of Darzalex Faspro For The Treatment Of Light Chain Amyloidosis

Published: 09/10/2020 12:03 GMT
Johnson & Johnson (JNJ) - Janssen Submits Application Seeking U.S. FDA Approval of Darzalex Faspro™ (daratumumab and Hyaluronidase-fihj) for the Treatment of Patients With Light Chain (al) Amyloidosis.
Janssen Pharmaceutical Companies - Sbla is Being Reviewed Under FDA Real-time Oncology Review (rtor) Program.
Revenue is expected to be $22.52 Billion
Adjusted EPS is expected to be $2.29

Next Quarter Revenue Guidance is expected to be $23.45 Billion
Next Quarter EPS Guidance is expected to be $2.40

More details on our Analysts Page.